Trial Profile
Effect of a Fixed Dose Combination Formulation of Daclatasvir/Asunaprevir/BMS-791325 on the Pharmacokinetics of a Cocktail of CYP Probe Substrates (Caffeine, Metoprolol, Montelukast, Flurbiprofen, Omeprazole, and Midazolam) and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Asunaprevir/becabluvir/daclatasvir (Primary) ; Beclabuvir
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
- 19 Dec 2017 Results published in the Drugs in R and D
- 05 May 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Feb 2014 New trial record